U.S. Gas Utilities Stock News

Why Catalyst Pharmaceuticals Stock Is On Investors’ Radar Catalyst Pharmaceuticals (CPRX) has drawn attention after a period of strong share-price moves, with returns over the past month, past 3 months and year all in positive territory according to recent performance data. For investors tracking US biopharmaceutical stocks focused on rare diseases, this kind of sustained positive return profile can prompt a closer look at how the current share price relates to earnings, profitability and...

Cimpress plc has reported past third-quarter 2026 results showing sales of US$886.21 million versus US$789.47 million a year earlier, with net income of US$13.84 million compared with a net loss of US$8.24 million and basic earnings per share from continuing operations improving from US$0.33 loss to US$0.57. Over the first nine months to March 31, 2026, Cimpress lifted sales to US$2.79 billion and more than doubled net income to US$70.82 million, highlighting materially stronger...

Jacobs Solutions (NYSE:J) has been selected as part of a joint venture to design five new underground stations for Sydney Metro West. The contract covers integrated engineering design services for Australia’s largest transportation project. The win expands Jacobs Solutions’ global transportation infrastructure footprint, with a focus on high-performance, sustainable mass transit. For investors watching the infrastructure and engineering space, this new Sydney Metro West mandate puts Jacobs...

Stepan Company reported past first-quarter 2026 results showing sales of US$604.51 million versus US$593.26 million a year earlier, but it swung from net income of US$19.71 million to a net loss of US$41.41 million, with basic and diluted loss per share from continuing operations of US$1.81 compared with earnings of US$0.86. Despite the move into loss-making territory, Stepan maintained its shareholder payout by affirming a quarterly dividend of US$0.395 per share, payable on June 15, 2026,...

IHS Holding (NYSE:IHS) has completed the divestment of its 51% stake in Brazilian fiber infrastructure venture I-Systems. The stake has been sold to TIM S.A., marking IHS Holding's exit from this Brazilian optical fiber joint venture. IHS Holding, trading at $8.23, has seen its stock return 12.0% year to date and 44.1% over the past year, while its 3 year return stands at 9.2%. This completed I-Systems divestment gives investors a fresh development to consider alongside those share price...

Albemarle (NYSE:ALB) held its annual shareholder meeting on May 5, 2026. Shareholders approved the board slate, executive compensation package, and auditor ratification. A proposal to remove supermajority provisions for certain affiliated transactions narrowly did not pass. Shareholders backed a proposal to make it easier for investors to call special meetings. Albemarle, a major producer in the lithium and specialty chemicals space, sits at the center of debates around corporate governance...

Encompass Health (EHC) stock is in focus after first quarter 2026 results topped Wall Street expectations, management raised full year revenue and adjusted EPS guidance, and the company continued expanding its inpatient rehabilitation hospital network. See our latest analysis for Encompass Health. The recent 1 day share price return of 2.0% to $107.15 and 7 day share price return of 7.2% suggest momentum has picked up following the earnings beat, higher guidance, new hospital opening and...

Wondering if Maximus stock is offering fair value or a potential bargain right now, especially after a tough stretch for returns. The share price last closed at US$66.66, with Maximus delivering a 1.6% return over the past week and 2.3% over the last month, but a 22.9% decline year to date and a 10.6% decline over the last year hint at changing sentiment. Recent coverage has focused on how Maximus fits into investors' long term portfolios and whether the current price reflects its...

RenaissanceRe Holdings (NYSE:RNR) has appointed Henry Klehm III as Non-Executive Chair, succeeding the company’s long-serving board leader. The board also renewed its share repurchase program, authorizing up to $750 million of buybacks. These moves highlight changes in board oversight and capital allocation at a time when the stock trades around $300.84. RenaissanceRe Holdings comes into this leadership change with the stock at $300.84 and multi year share price gains, including 10.5% year...

If you are wondering whether DNOW stock offers value at today’s price, the key question is how that price lines up with the company’s underlying fundamentals. The stock last closed at US$13.05, with returns of 6.3% over 30 days, a 3.3% decline over 7 days, a 2.3% decline year to date, and a 10.2% decline over 1 year. The 3 year and 5 year returns sit at 43.1% and 19.8% respectively. These mixed returns highlight that sentiment around DNOW can shift over different time frames. This often...

If you are wondering whether Dynex Capital's current share price offers good value or carries more risk than reward, the starting point is to look closely at how it stacks up on valuation. The stock recently closed at US$13.32, with a 7 day return of 2.2% decline, a 30 day return of 5.0%, a year to date return of 5.4% decline, and a 1 year return of 25.5%, which gives you a mix of short term setbacks and longer term gains to weigh up. Recent coverage around Dynex Capital has focused on how...

Xeris Biopharma Holdings (XERS) stock is in focus after the company reported a profitable first quarter of 2026 and raised its full year revenue guidance to US$380 million to US$390 million. See our latest analysis for Xeris Biopharma Holdings. The guidance hike and first quarter profit have come after a mixed period for the stock, with a 12.95% 1 month share price return and a 9.80% year to date share price decline. At the same time, 1 year and 3 year total shareholder returns of 28.49% and...

Sotera Health (SHC) just delivered a busy first quarter, pairing 10% year-over-year revenue growth and a move back to profitability with reaffirmed 2026 guidance and a planned CEO transition. See our latest analysis for Sotera Health. The share price is US$15.67 after a 7.04% 1 month share price return. However, the 90 day share price return of 11.72% and year to date share price return of 11.42% suggest recent momentum has cooled. Even so, the 1 year total shareholder return of 18.44% and 3...

Inflation jitters, higher energy costs and uneven global growth are putting a spotlight on company quality. When price pressures, shifting trade flows and rate expectations keep markets on edge, stocks with high return on equity, solid past performance and strong balance sheets can offer a more direct way to focus on business strength rather than noise. This article uses our Solid Balance Sheet and Fundamentals screener to highlight 3 stocks that fit this quality filter, helping you focus on...

Why AtriCure (ATRC) Is On Investors’ Radar Today AtriCure (ATRC) has drawn fresh attention as investors reassess the stock after a difficult stretch, with negative returns over the past month, past 3 months, year to date, and over the past year. See our latest analysis for AtriCure. At a share price of $27.80, AtriCure has seen weaker short term momentum, with a 30 day share price return of a 3.77% decline and a 1 year total shareholder return of a 10.84% loss pointing to prolonged...

Rising inflation surprises, volatile energy and food prices, and mixed signals on growth are keeping markets jumpy, while the world’s appetite for electricity-intensive AI and low carbon power keeps building. For investors, that combination puts long term, round the clock clean energy at the center of many big spending plans. The Nuclear Renaissance screener focuses on companies tied to this push for reliable, carbon free power linked to major infrastructure commitments rather than short term...

Q1 earnings turnaround draws fresh attention Alto Ingredients (ALTO) has caught investor interest after reporting first quarter 2026 net income of US$4.27 million, a shift from an US$11.68 million net loss in the same period a year earlier. Sales for the quarter were US$224.68 million compared with US$226.54 million a year ago, while both basic and diluted earnings per share from continuing operations came in at US$0.05 versus a basic and diluted loss per share of US$0.16 previously. See our...

Church & Dwight Co., Inc. recently reported first-quarter 2026 results showing sales of US$1,469.3 million and net income of US$216.3 million, affirmed a quarterly dividend of US$0.3075 per share, and issued guidance for a 1% reported sales decline for the June 2026 quarter due to prior portfolio actions. Management highlighted that growth in key brands such as ARM & HAMMER and THERABREATH, alongside online sales reaching nearly 24% of global consumer sales, is supporting underlying...

If you are wondering whether Genpact at around US$34.48 is a bargain or a value trap, the key is understanding what the current price really reflects. Over the short term, the stock has seen a 0.8% decline over 7 days, an 8.0% decline over 30 days, and is down 24.9% year to date, with a 16.6% decline over 1 year and a near flat 0.3% return over 3 years, compared with a 17.0% decline over 5 years. Recent coverage around Genpact has focused on how the business is positioned in professional...

What Republic Airways Holdings (RJET) Offers Investors Today Republic Airways Holdings (RJET) operates scheduled passenger services with about 275 aircraft and 1,300 daily flights across 130 cities in the United States, Canada, the Caribbean, and Mexico. The company reported revenue of US$1,809.1 million and net income of US$76.0 million. The stock most recently closed at US$22.39, with reported returns of 10.51% over the past day, 34.39% over the past week, 21.82% over the past month, and...

SES AI stock performance snapshot SES AI (SES) has drawn fresh attention as investors reassess high risk battery technology stocks, with the share price recently closing at US$0.92 and the market cap sitting near US$362.7m. See our latest analysis for SES AI. The recent 1 day share price return of a 6.24% decline, alongside a 7 day share price return of a 12.29% decline and a 90 day share price return of a 51.01% decline, contrasts with a 1 year total shareholder return of 2.19%. This...

Q1 2026 earnings put Eve Holding in focus Eve Holding (EVEX) is back on investors’ radar after reporting a wider first quarter 2026 loss, updating its eVTOL commercialization timeline, and outlining progress on certification and prototype flight testing. See our latest analysis for Eve Holding. The earnings update and prototype milestones have come after a mixed run for the stock, with a 24.9% 1 month share price return but a 23.39% year to date share price decline and a 59.82% 3 year total...

In early May 2026, Artivion, Inc. reported first‑quarter revenue of US$116.34 million, up from US$98.98 million a year earlier, and moved from a small net loss to a net income of US$1.42 million while also announcing plans to acquire Endospan following FDA approval of the NEXUS Aortic Arch System. Despite this topline growth and portfolio expansion, Artivion missed profit expectations and lowered its full‑year 2026 revenue and adjusted EBITDA guidance, highlighting near‑term operational...

Why Crane NXT stock is back in focus after Q1 Crane NXT (CXT) is drawing fresh attention after first quarter 2026 revenue and adjusted earnings topped expectations, helped by the Antares Vision acquisition and firm demand in Security and Authentication Technologies. See our latest analysis for Crane NXT. The latest results and acquisition update have arrived after a mixed share price run, with a 30 day share price return of 5.40% but a 1 year total shareholder return decline of 12.80%. If Q1...